Ph3 open-label study to TATE in patients newly diagnosed with GEP-NET (NETTER-3)
Phase III Clinical Trial
A phase III multi-center randomized open-label study to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients newly diagnosed with Grade 1 and Grade 2 (Ki-67 <10%) advanced GEP-NET with high disease burden (NETTER-3) Protocol No.: CAAA601A62301